Berkeley Inc Grows Position in Zoetis Inc. $ZTS

Berkeley Inc grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 20.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 52,317 shares of the company’s stock after purchasing an additional 8,772 shares during the period. Zoetis makes up about 2.5% of Berkeley Inc’s holdings, making the stock its 13th largest position. Berkeley Inc’s holdings in Zoetis were worth $7,655,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ZTS. Vanguard Group Inc. increased its holdings in Zoetis by 0.8% in the second quarter. Vanguard Group Inc. now owns 41,886,987 shares of the company’s stock valued at $6,532,276,000 after buying an additional 330,823 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Zoetis by 0.9% in the 2nd quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock worth $1,721,356,000 after acquiring an additional 95,294 shares during the period. Norges Bank purchased a new position in Zoetis in the 2nd quarter valued at approximately $809,491,000. Brown Advisory Inc. raised its holdings in Zoetis by 5.7% during the second quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock worth $726,629,000 after purchasing an additional 250,829 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Zoetis by 113.0% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock worth $586,671,000 after purchasing an additional 1,995,491 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 1.1%

Shares of ZTS opened at $123.24 on Wednesday. The stock has a fifty day moving average of $123.37 and a two-hundred day moving average of $138.85. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The company has a market capitalization of $54.31 billion, a PE ratio of 20.75, a price-to-earnings-growth ratio of 2.53 and a beta of 0.97. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.40.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.08. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business’s revenue was up .5% on a year-over-year basis. During the same quarter last year, the firm earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be issued a $0.53 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of research analyst reports. Barclays started coverage on Zoetis in a research report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target for the company. Stifel Nicolaus cut their target price on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. HSBC set a $140.00 price target on shares of Zoetis in a report on Wednesday, December 10th. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. Finally, JPMorgan Chase & Co. reduced their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $160.18.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.